ELVN — Enliven Therapeutics, Inc. stock price, charts and financials

Latest market price

58.04

+3.23+5.89%

Overview Short InterestFilings

ELVNQT90Enliven Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

58.04+5.89%

Loading chart...

Screen all →

CPRX+0.00%$31.49 EWTX-0.13%$38.38 VKTX+2.74%$32.61 DNLI+0.56%$23.15 CELC+1.55%$87.72 PRTC+4.51%$17.38 ORKA-1.78%$94.79 ADPT+2.39%$23.11

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	36.58%	Shs Outstand	71.44M	Perf Week	3.51%

Market Cap	3.92B	Forward P/E	-	EPS next Y	-2.31	Insider Trans	-5.13%	Shs Float	45.61M	Perf Month	12.41%

Enterprise Value	3.78B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	18.97%	Perf Quarter	32.94%

Income	-112.38M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	6.60	Perf Half Y	113.52%

Sales	0.00	P/B	7.59	EPS next Y	-35.30%	ROA	-21.25%	Short Interest	8.65M	Perf YTD	255.91%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-21.04%	52W High	59.11 -1.81%	Perf Year	183.70%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-25.52%	52W Low	15.66 270.59%	Perf 3Y	201.32%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	4.67% 4.70%	Perf 5Y	154.69%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	11.64%	Oper. Margin	0.00%	ATR (14)	2.57	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	40.32	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	63.41	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	40.32	EPS Q/Q	33.33%	SMA20	4.63%	Beta	0.25	Target Price	70.80

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	17.79%	Rel Volume	0.51	Prev Close	54.81

Employees	61	LT Debt/Eq	-0.06	Earnings	Aug 12	SMA200	67.09%	Avg Volume	1.30M	Price	58.04

IPO Date	Mar 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.34% -	Net Debt/EBITDA	1.34	Volume	660,418	Change	5.89%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-21-26	Reiterated	Goldman Sachs	Buy	$59 → $67
Jul-09-26	Reiterated	HC Wainwright & Co.	Buy	$39 → $65
Jul-01-26	Reiterated	Stifel Nicolaus		$60 → $80
Jun-08-26	Initiated	Stifel	Buy	$60
Jun-02-26	Reiterated	Mizuho	Outperform	$39 → $62
May-12-26	Initiated	Guggenheim	Buy	$80
May-08-26	Reiterated	Goldman Sachs	Buy	$59
Jun-16-25	Reiterated	Robert W. Baird		$40 → $52
Mar-21-25	Reiterated	HC Wainwright & Co.	Buy	$39
Nov-15-24	Reiterated	Robert W. Baird		$32 → $40

Latest News

Jul-21-26

Jul-21-2608:40AM

Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $67Benzinga

Jul-09-26

Jul-09-2606:22AM

HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $64Benzinga

Jul-01-26

Jul-01-2610:02AM

Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $80Benzinga

Jun-27-26

Jun-27-2603:36PM

What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%fool.com

12:03PM

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rallyfool.com

Jun-22-26

Jun-22-2610:55AM

Enliven Therapeutics: Continuing The Pop Off; What Could Go Wrong?SeekingAlpha

Jun-15-26

Jun-15-2607:04PM

Enliven Therapeutics, Inc. (ELVN) Presents at European Hematology Association (EHA) 2026 Congress - SlideshowSeekingAlpha

Jun-12-26

Jun-12-2601:31AM

Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia - SlideshowSeekingAlpha

Jun-11-26

Jun-11-2602:42PM

Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia TranscriptSeekingAlpha

11:44AM

Crude Oil Edges Higher; Driven Brands Posts Upbeat EarningsBenzinga

10:10AM

Stitch Fix, Intel, KLA And Other Big Stocks Moving Higher On ThursdayBenzinga

08:57AM

Enliven Therapeutics Presents Data From The Phase 1 Enable Clinical Trial Evaluating ELVN-001 In Patients With Previously Treated Chronic Myeloid Leukemia; Notes Encouraging Efficacy Data By 24 WeeksBenzinga

Company

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	0	0	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0	0	0	0
Selling, General and Administrative Excl. Other	34	24	19	8	4	1	5	2	1
Research and Development	86	81	65	31	20	8	19	8	8
Other Operating Expense	-1	0	0	0	1	0	0	1	0
Operating Income	-120	-105	-84	-39	-25	-9	-24	-11	-9
Interest Expense	0	0	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	16	16	12	1	0	-10	1	-1	9
Net Income Before Taxes	-104	-89	-72	-38	-25	-19	-23	-11	0
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-104	-89	-72	-38	-25	-19	-23	-11	0
Net Income From Continuing Operations	-104	-89	-72	-38	-25	-19	-23	-11	0
Net Income	-104	-89	-72	-38	-25	-19	-23	-11	0
EPS (Recurring)	-1.83	-1.89	-2.01	-6.03	-3.17	-4.31	-5.43	-2.62	0.00
EPS (Basic, Before Extraordinaries)	-1.83	-1.89	-2.01	-6.03	-3.17	-4.31	-5.43	-2.62	0.00
EPS (Diluted)	-1.83	-1.89	-2.01	-6.03	-3.17	-4.31	-5.43	-2.62	0.00
EBITDA	-103	-88	-71	-37	-25	-9	-23	-11	0
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	57	47	36	6	8	4	4	4	4
Market Capitalization	878	1,058	498	98	72	353	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 17 '26	Sale	52.64	6,018	316,780	46,054	Jul 21
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 17 '26	Option Exercise	2.48	1,072	2,659	52,072	Jul 21
Collins Helen Louise	CHIEF MEDICAL OFFICER	Jul 17 '26	Option Exercise	2.48	5,000	12,400	30,000	Jul 21
Collins Helen Louise	CHIEF MEDICAL OFFICER	Jul 17 '26	Sale	52.67	5,000	263,374	25,000	Jul 21
Kunkel Lori Anne	Director	Jul 06 '26	Sale	50.49	10,000	504,903	41,884	Jul 08
ORBIMED ADVISORS LLC	10% Owner	Jun 22 '26	Sale	45.36	860,123	39,014,045	219,405	Jun 24
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 17 '26	Option Exercise	2.48	6,018	14,925	57,018	Jun 22
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 17 '26	Sale	43.80	6,018	263,577	51,000	Jun 22
Collins Helen Louise	CHIEF MEDICAL OFFICER	Jun 17 '26	Option Exercise	2.48	5,000	12,400	30,000	Jun 22
Collins Helen Louise	CHIEF MEDICAL OFFICER	Jun 17 '26	Sale	43.80	5,000	219,017	25,000	Jun 22
ORBIMED ADVISORS LLC	10% Owner	Jun 15 '26	Sale	45.02	281,408	12,668,988	245,728	Jun 17
Kunkel Lori Anne	Director	Jun 05 '26	Sale	34.54	10,000	345,351	51,884	Jun 09
Collins Helen Louise	CHIEF MEDICAL OFFICER	May 18 '26	Option Exercise	2.48	5,000	12,400	30,000	May 20
Collins Helen Louise	CHIEF MEDICAL OFFICER	May 18 '26	Sale	39.79	5,000	198,972	25,000	May 20
Collins Helen Louise	CHIEF MEDICAL OFFICER	Apr 17 '26	Sale	47.67	5,000	238,351	25,000	Apr 21

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.